1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Dysmenorrhea Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness about women’s reproductive health
5.1.1.2. Government initiatives and healthcare programs to expand access to healthcare for women
5.1.1.3. Rising number of clinical trials and investments by life sciences industries
5.1.2. Restraints
5.1.2.1. Lack of reimbursement and difficulty in availing of insurance coverage
5.1.3. Opportunities
5.1.3.1. Advancements in therapy for dysmenorrhea and the emergence of novel drugs
5.1.3.2. Adoption of wearable technology and the proliferation of digital health
5.1.4. Challenges
5.1.4.1. Stringent regulations concerning drug approval for dysmenorrhea treatment
5.2. Market Segmentation Analysis
5.2.1. Type: Wide occurrence of primary dysmenorrhea and extensive need for pain relief management
5.2.2. Treatment: Adoption of hysterectomy treatment to provide permanent relief from dysmenorrhea
5.2.3. Distribution Channel: Growing preference for online pharmacies due to their convenience, discreteness, and competitive pricing of medications and pain relief patches
5.2.4. End-Users: Increasing adoption of dysmenorrhea treatment in the homecare segment as it is easily accessible and cost-effective
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Dysmenorrhea Treatment Market, by Type
6.1. Introduction
6.2. Primary Dysmenorrhea
6.3. Secondary Dysmenorrhea
7. Dysmenorrhea Treatment Market, by Treatment
7.1. Introduction
7.2. Medication
7.3.1. Combined Oral Contraceptive Pills
7.3.2. Cox-2 Inhibitors
7.3.3. Non-Steroidal Anti-Inflammatory Drugs
7.3.4. Over-The-Counter Medications
7.3.5. Transdermal Glyceryl Trinitrate
7.3. Surgery
7.4.1. Hysterectomy
7.4.2. Intrauterine Device
7.4.3. Laparoscopic Uterosacral Nerve Ablation
7.4.4. Levonorgestrel Intrauterine System (LN-IUS)
7.4.5. Presacral Neurectomy
7.4. Therapeutics
8. Dysmenorrhea Treatment Market, by Distribution Channel
8.1. Introduction
8.2. Hospital Pharmacy
8.3. Online Pharmacy
8.4. Retail Pharmacy
9. Dysmenorrhea Treatment Market, by End-Users
9.1. Introduction
9.2. Homecare
9.3. Hospitals
9.4. Specialty Clinics
10. Americas Dysmenorrhea Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Dysmenorrhea Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Dysmenorrhea Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
13.3.1. Agreement, Collaboration, & Partnership
13.3.1.1. Chugai and Biofourmis Enter into New Partnership Focused on Data-Driven Virtual Care for Endometriosis-Related Pain
13.3.2. New Product Launch & Enhancement
13.3.2.1. Daré Bioscience Begins Phase I Trial of Primary Dysmenorrhea Therapy
13.3.3. Investment & Funding
13.3.3.1. Mithra to Receive EUR 2.5 Million from Fuji Pharma for Dysmenorrhea Treatment in Japan
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. AA Pharma Inc.
14.1.2. Abbott Laboratories
14.1.3. AbbVie Inc.
14.1.4. Alfa Pharma GmbH
14.1.5. Allergan PLC
14.1.6. Alvogen, Inc.
14.1.7. Bayer AG
14.1.8. Chugai Pharmaceutical Co., Ltd.
14.1.9. Cora Life by LYV Life, Inc.
14.1.10. Cumberland Pharmaceuticals Inc.
14.1.11. Dr. Reddy’s Laboratories
14.1.12. Endo Pharmaceuticals Inc.
14.1.13. F. Hoffmann-La Roche Ltd.
14.1.14. Ferring B.V.
14.1.15. GlaxoSmithKline PLC
14.1.16. Hikma Pharmaceuticals PLC
14.1.17. Johnson & Johnson Services, Inc.
14.1.18. Lupin Pharmaceuticals, Inc.
14.1.19. Merck & Co., Inc.
14.1.20. Micro Labs Limited
14.1.21. Mylan N.V. by Viatris Inc.
14.1.22. Myoovi
14.1.23. Myovant Sciences
14.1.24. Ovira
14.1.25. Perrigo Corporation
14.1.26. Pfizer Inc.
14.1.27. PMS4PMS, LLC
14.1.28. Sanofi S.A.
14.1.29. Sun Pharmaceutical Industries Ltd.
14.1.30. Takeda Pharmaceutical Company Limited.
14.1.31. Teva Pharmaceutical Industries Ltd.
14.1.32. Walgreen Co.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
